FDA Commissioner Marty Makary has selected experienced biotech vet George Tidmarsh, M.D., Ph.D., as the next head of the FDA’s Center for Drug Evaluation and Research (CDER).
Tidmarsh assumes leadership of CDER after a distinguished career in biotechnology and academia, during which he contributed to the approval of seven FDA-approved drugs, cofounded several biopharma companies, and helped launch Stanford’s M-TRAM program. A recognized biotech vet, he brings decades of cross-sector experience to the role. BioSpace+3U.S. Food and Drug Administration+3U.S. Food and Drug Administration+3
Over years, as a biotech vet, Dr. Tidmarsh has founded and led companies including Revelation Biosciences, Metronome Therapeutics, and Horizon Therapeutics (later acquired by Amgen for nearly $28 billion). He has served on numerous industry and academic boards, translating scientific discoveries into commercial therapies. U.S. Food and Drug Administration+3Akin – Akin, an Elite Global Law Firm+3BioSpace+3
In announcing the appointment, Commissioner Makary described Tidmarsh as a physician, innovator, and regulatory strategist whose leadership as a biotech vet will strengthen FDA’s drug review programs and foster scientific rigor. U.S. Food and Drug Administration+2Reuters+2 Makary committed to collaborating with him on modernizing review processes, encouraging innovation, and reinforcing public health objectives.
The precise priorities of Tidmarsh within CDER are not yet confirmed, but as a biotech vet, he has publicly voiced interest in removing ineffective or harmful drugs, raising research integrity standards, and holding institutions accountable for scientific misconduct. His background suggests he may push for stricter post-market surveillance and faster pivots in regulatory policy.
He takes over from Jacqueline Corrigan-Curay, who served as interim director following Patrizia Cavazzoni’s departure. Corrigan-Curay announced her upcoming retirement, facilitating a smoother handover. RAPS+1
Tidmarsh’s appointment comes amid broader shifts in the FDA’s leadership. Nicole Verdun, M.D., formerly overseeing gene and cell therapy, and her deputy, Rachael Anatol, were reportedly placed on leave in June. Hilary Marston, the FDA’s Chief Medical Officer, left in April. Meanwhile, Peter Marks, former head of the biologics division (CBER), resigned in April, citing disagreements over vaccination policy. Reuters+4Gastroenterology Advisor+4BioSpace+4
Following Marks’s exit, Makary named Vinay Prasad to lead CBER. Together, Prasad and Tidmarsh will now occupy two of the most influential roles in FDA’s pharmaceutical oversight. As a biotech vet, Tidmarsh’s ability to navigate industry, academia, and regulatory realms may prove pivotal in coordinating the agency’s evolving policy agenda. Fierce Pharma+2BioSpace+2
Additional Content: Perspectives & Implications
Leadership Style Rooted in Industry & Science
As a longtime biotech vet, Tidmarsh is expected to bring a data-driven, translational mindset to regulatory strategy. He has often emphasized bridging gaps between lab discoveries and patient outcomes—a philosophy rooted in his work with academic and commercial ventures. His dual identity as a clinician and entrepreneur could reshape how CDER balances scientific risk, innovation, and public safety.
Challenges Ahead in Regulation & Innovation
Taking the helm during a turbulent time, Tidmarsh inherits major responsibilities: speeding up approvals, enhancing post-market safety monitoring, adjusting to political and public pressures, and reimagining drug oversight in an era of complex therapies. As a biotech vet, his experience may help him manage pressures from industry stakeholders, patient advocacy groups, and policymakers—mediating tensions while preserving the FDA’s mission.
Potential Focus Areas for Change
-
Modernizing review algorithms & digital tools: Tidmarsh is well suited to push for increased use of artificial intelligence and real-world evidence in drug reviews
-
Enhancing transparency & scientific integrity: Having previously criticized research malpractice, he may champion reforms in data sharing, reproducibility, and trial registration
-
Bridging regulatory and commercialization incentives: With his commercial background as a biotech vet, he may foster more predictable pathways for innovative therapies while preserving regulatory rigor
-
Addressing leadership gaps across FDA centers: Already, reports suggest he may assume oversight of CBER in addition to CDER during leadership transitions. BioSpace+1
Tidmarsh’s appointment as CDER director marks a new chapter at the FDA, one in which a seasoned biotech vet assumes a leading role at the intersection of innovation, regulation, and public health. How he balances those demands will shape the agency’s direction and its influence on drug development worldwide.
